MultiSCRIPT-Cycle 1—a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial

Autor: Perrine Janiaud, Chiara Zecca, Anke Salmen, Pascal Benkert, Sabine Schädelin, Annette Orleth, Lilian Demuth, Aleksandra Maleska Maceski, Cristina Granziera, Johanna Oechtering, David Leppert, Tobias Derfuss, Lutz Achtnichts, Oliver Findling, Patrick Roth, Patrice Lalive, Marjolaine Uginet, Stefanie Müller, Caroline Pot, Robert Hoepner, Giulio Disanto, Claudio Gobbi, Leila Rooshenas, Matthias Schwenkglenks, Mark J. Lambiris, Ludwig Kappos, Jens Kuhle, Özgür Yaldizli, Lars G. Hemkens

Publikováno v: Trials, Vol 25, Iss 1, Pp 1-12 (2024)

Abstract Background Treatment decisions for persons with relapsing–remitting multiple sclerosis (RRMS) rely on clinical and radiological disease activity, the benefit-harm profile of drug therapy, and preferences of patients and physicians. However

Externí odkaz: https://doaj.org/article/2dbdfb286bde4ad5a8fa355b8dcd0b9d

Serum tau protein elevation in migraine: a cross-sectional case–control study

Autor: Lucas Hendrik Overeem, Bianca Raffaelli, Robert Fleischmann, Marie Süße, Antje Vogelgesang, Aleksandra Maleska Maceski, Athina Papadopoulou, Klemens Ruprecht, Wendy Su, Mirja Koch, Anke Siebert, Michal Arkuszewski, Nadia Tenenbaum, Jens Kuhle, Uwe Reuter

Publikováno v: The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-11 (2023)

Abstract Background Migraine is a disorder associated with neuropeptide release, pain and inflammation. Tau protein has recently been linked to inflammatory diseases and can be influenced by neuropeptides such as CGRP, a key neurotransmitter in migra

Externí odkaz: https://doaj.org/article/324d4772a1664655906ce353a7b96de0

Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis

Autor: Stephanie Meier, Eline A.J. Willemse, Sabine Schaedelin, Johanna Oechtering, Johannes Lorscheider, Lester Melie-Garcia, Alessandro Cagol, Muhamed Barakovic, Riccardo Galbusera, Suvitha Subramaniam, Christian Barro, Ahmed Abdelhak, Simon Thebault, Lutz Achtnichts, Patrice Lalive, Stefanie Müller, Caroline Pot, Anke Salmen, Giulio Disanto, Chiara Zecca, Marcus D’Souza, Annette Orleth, Michael Khalil, Arabella Buchmann, Renaud Du Pasquier, Özgür Yaldizli, Tobias Derfuss, Klaus Berger, Marco Hermesdorf, Heinz Wiendl, Fredrik Piehl, Marco Battaglini, Urs Fischer, Ludwig Kappos, Claudio Gobbi, Cristina Granziera, Claire Bridel, David Leppert, Aleksandra Maleska Maceski, Pascal Benkert, Jens Kuhle

Publikováno v: Meier, S, Willemse, E A J, Schaedelin, S, Oechtering, J, Lorscheider, J, Melie-Garcia, L, Cagol, A, Barakovic, M, Galbusera, R, Subramaniam, S, Barro, C, Abdelhak, A, Thebault, S, Achtnichts, L, Lalive, P, Müller, S, Pot, C, Salmen, A, Disanto, G, Zecca, C, D'souza, M, Orleth, A, Khalil, M, Buchmann, A, du Pasquier, R, Yaldizli, Ö, Derfuss, T, Berger, K, Hermesdorf, M, Wiendl, H, Piehl, F, Battaglini, M, Fischer, U, Kappos, L, Gobbi, C, Granziera, C, Bridel, C, Leppert, D, Maleska Maceski, A, Benkert, P & Kuhle, J 2023, ' Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis ', JAMA Neurology, vol. 80, no. 3, pp. 287-297 . https://doi.org/10.1001/jamaneurol.2022.5250
JAMA Neurology, 80(3), 287-297. American Medical Association

ImportanceThere is a lack of validated biomarkers for disability progression independent of relapse activity (PIRA) in multiple sclerosis (MS).ObjectiveTo determine how serum glial fibrillary acidic protein (sGFAP) and serum neurofilament light chain

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67e0429aeff47b5cc00aef28b955a5e9
https://doi.org/10.1001/jamaneurol.2022.5250

Serum Glial Fibrillary Acidic Protein compared with Neurofilament Light Chain as Biomarker for Multiple Sclerosis Disease Progression (P5-3.016)

Autor: Stephanie Meier, Pascal Benkert, Aleksandra Maleska Maceski, Sabine Schaedelin, Johanna Oechtering, Lester Melie-Garcia, Alessandro Cagol, Muhamed Barakovic, Riccardo Galbusera, Lutz Achtnichts, Patrice H. Lalive, Claire Bridel, Stefanie Müller, Caroline Pot, Anke Salmen, Giulio Disanto, Chiara Zecca, Ahmed Abdelhak, Christian Barro, Simon Thebault, Marcus D’Souza, Tobias Derfuss, Annette Orleth, Michael Khalil, Özguer Yaldizli, Marco Hermesdorf, Heinz Wiendl, Fredrik Piehl, Urs Fischer, Ludwig Kappos, Claudio Gobbi, Cristina Granziera, David Leppert, Eline A.J. Willemse, Jens Kuhle

Publikováno v: Monday, April 24.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::186b49cec9161825dfa1433e923f4118
https://doi.org/10.1212/wnl.0000000000203030

Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity

Autor: Claire Duflos, Jeremy Deverdun, Frédéric Pinna, Tobias Kober, Clarisse Carra-Dalliere, Bénédicte Maréchal, Ricardo Corredor Jerez, Christophe Hirtz, Pauline Prin, Xavier Ayrignac, Nicolas Menjot de Champfleur, Sylvain Lehmann, Mahmoud Charif, Mário João Fartaria, Pierre Labauge, Aleksandra Maleska Maceski, Emmanuelle Le Bars

Publikováno v: Scientific Reports, Vol 10, Iss 1, Pp 1-5 (2020)
Scientific Reports
Scientific Reports, 2020, 10 (1), pp.10923. ⟨10.1038/s41598-020-67934-2⟩
Scientific Reports, Nature Publishing Group, 2020, 10 (1), pp.10923. ⟨10.1038/s41598-020-67934-2⟩

Neurofilament light chain (NfL) has been demonstrated to correlate with multiple sclerosis disease severity as well as treatment response. Nevertheless, additional serum biomarkers are still needed to better differentiate disease activity from diseas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ceeefd830440650513f7ee787b0942de
http://link.springer.com/article/10.1038/s41598-020-67934-2